Mesoblast Limited (NASDAQ:MESO) Short Interest Update

Mesoblast Limited (NASDAQ:MESO) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,800,000 shares, an increase of 34.3% from the December 15th total of 1,340,000 shares. Based on an average trading volume of 384,900 shares, the short-interest ratio is currently 4.7 days.

Mesoblast Stock Performance

Shares of MESO stock traded down $0.43 during mid-day trading on Thursday, hitting $16.67. 543,629 shares of the company’s stock were exchanged, compared to its average volume of 655,004. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. Mesoblast has a fifty-two week low of $1.61 and a fifty-two week high of $22.00. The stock has a 50-day simple moving average of $13.76 and a two-hundred day simple moving average of $9.69.

Institutional Investors Weigh In On Mesoblast

Hedge funds have recently modified their holdings of the stock. Signaturefd LLC raised its holdings in shares of Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after purchasing an additional 3,099 shares during the period. Perkins Coie Trust Co lifted its position in Mesoblast by 15.0% during the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after buying an additional 1,500 shares in the last quarter. Rathbones Group PLC purchased a new stake in Mesoblast during the second quarter worth approximately $95,000. XTX Topco Ltd acquired a new stake in shares of Mesoblast in the second quarter worth $103,000. Finally, GAMMA Investing LLC raised its stake in shares of Mesoblast by 22.1% in the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after acquiring an additional 1,213 shares during the period. 1.43% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on MESO shares. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Tuesday, September 24th. Piper Sandler increased their price objective on Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th. Finally, Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $13.50.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.